Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24809669 | 0.86 | IRAK4 (0.43) | CYP1A2CYP2C9 | |
| SCHEMBL21024668 | 0.85 | CYP1A2 (0.48) | CYP1A2CYP2C9POLBLRRK2PIK3CA | |
| SCHEMBL10094245 | 0.85 | CYP1A2 (0.49) | CYP1A2CYP2C9MAPK1KDM4ELMNA | |
| SCHEMBL26790144 | 0.85 | CYP1A2 (0.45) | CYP1A2CYP2C9KDM4E | |
| SCHEMBL13018542 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2C9POLBLRRK2PIK3CA | |
| SCHEMBL2609324 | 0.83 | CYP1A2 (0.51) | CYP1A2CYP2C9KDM4ELMNA | |
| SCHEMBL10094221 | 0.82 | MAPK1 (0.46) | CYP1A2CYP2C9POLBLRRK2PIK3CA | |
| SCHEMBL19107154 | 0.82 | HRH4 (0.50) | — | |
| SCHEMBL10094261 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP2C9POLBLRRK2PIK3CA | |
| SCHEMBL19107153 | 0.81 | EPHX2 (0.55) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20210047363-A1 | 17-BETA-HYDROXYWITHANOLIDES AND USE THEREOF IN TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829480-B2 | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives | GRUENENTHAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2010101949-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010077686-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010056549-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, ARRB1 | CYP1A2 191/4885CYP2C9 727/4885POLB 2418/4885 |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | AZI2, FURIN, ACE2 | CYP1A2 180/4885CYP2C9 441/4885POLB 4681/4885 |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | CYP1A2 2056/4885CYP2C9 1990/4885POLB 1676/4885 |
| US-20210047363-A1 | 17-BETA-HYDROXYWITHANOLIDES AND USE THEREOF IN TREATING CANCER | HSD17B7, CYP17A1, HSD17B11 | CYP1A2 330/4885CYP2C9 2834/4885POLB 3355/4885 |
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | HSD17B7, CYP17A1, HSD17B11 | CYP1A2 330/4885CYP2C9 2834/4885POLB 3355/4885 |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP1A2 1857/4885CYP2C9 2698/4885POLB 2217/4885 |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | AZI2, FURIN, ACE2 | CYP1A2 180/4885CYP2C9 441/4885POLB 4681/4885 |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | CYP1A2 1518/4885CYP2C9 1616/4885POLB 1265/4885 |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | CYP1A2 1423/4885CYP2C9 1569/4885POLB 785/4885 |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN7 | CYP1A2 2313/4885CYP2C9 1175/4885POLB 4586/4885 |
| US-10829480-B2 | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives | OPRD1, OPRK1, OPRL1 | CYP1A2 237/4885CYP2C9 750/4885POLB 2390/4885 |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP1A2 1236/4885CYP2C9 1458/4885POLB 612/4885 |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP1A2 1988/4885CYP2C9 3450/4885POLB 1122/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | CYP1A2 2371/4885CYP2C9 2201/4885POLB 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.